Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its news flow, as reflected in recent press releases and SEC filings, centers on clinical trial progress, scientific publications, financing activities and investor outreach related to its pipeline.
Investors following MNMD news can track updates on MM120, MindMed’s proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), which the company is developing for generalized anxiety disorder and major depressive disorder. Recent announcements have highlighted Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD and MDD, as well as the publication of a Phase 2b GAD trial in the Journal of the American Medical Association (JAMA). MindMed also issues news on MM402, its proprietary form of R(−)-MDMA being developed for core symptoms of autism spectrum disorder.
MindMed’s news releases frequently cover financial results, underwritten public offerings of common shares, and the intended use of proceeds to fund research and development and general corporate purposes. The company also announces participation in major healthcare and investor conferences, such as events hosted by J.P. Morgan, Stifel, Jefferies, Evercore and Piper Sandler, and provides details on investor webcasts and corporate presentations.
This MNMD news page aggregates these company-issued updates so readers can review clinical milestones, capital markets transactions, and corporate communications in one place. Regularly reviewing this information can help market participants understand how MindMed reports on the advancement of its brain health pipeline and its interactions with the investment community.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that the FDA has placed a clinical hold on its IND submission for the Phase 2b trial of LSD aimed at treating generalized anxiety disorder (GAD). This decision halts the initiation of the trial pending further information, which is expected within 30 days. CEO Robert Barrow expressed a commitment to address FDA concerns promptly. GAD affects approximately 6% of U.S. adults over their lifetimes, highlighting the need for innovative treatments.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has launched a Phase 2a exploratory trial studying the effects of low-dose lysergic acid diethylamide (LSD) for treating adult attention deficit hyperactivity disorder (ADHD). Conducted in collaboration with University Hospital Basel and Maastricht University, the trial aims to evaluate the therapeutic potential of repeated low doses of LSD. The study will enroll 52 patients over six weeks, analyzing ADHD symptom changes. This trial is part of MindMed's broader development strategy for LSD therapies.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Robert Barrow as CEO and Board member, effective immediately. Previously serving as interim CEO, Barrow brings extensive industry expertise, notably in psychedelic drug development. Carol Vallone has been appointed Chair of the Board, while Perry Dellelce transitions from Chairman. The company aims to advance its clinical development programs and expand its drug pipeline, focusing on psychedelic-inspired therapies for mental health.
On December 9, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its meeting with the FDA regarding the development of the MindMed Session Monitoring System. The meeting provided critical feedback on their draft Indications for Use (IFU) and research methods essential for regulatory submissions. The company presented a development roadmap to utilize advanced data collection and analysis techniques, aiming for regulatory approval of its innovative device. MindMed continues to emphasize its commitment to working closely with regulators to enhance the adoption of its technologies.
Mind Medicine (MindMed) (NASDAQ: MNMD) will participate in the Benzinga Global Small Cap Conference on December 8-9, 2021. CEO Robert Barrow will present a corporate update and engage in one-on-one investor meetings on December 9 at 4:00 p.m. ET. A webcast of the event will be available here and on MindMed's website for 30 days post-event. The company focuses on developing psychedelic therapies for addiction and mental illness.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced participation in the virtual H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO Robert Barrow will join a panel discussing The Future of Mental Healthcare at 2:30 p.m. ET. A webcast will be available on-demand starting at 7:00 a.m. ET on the same day. MindMed is a clinical-stage biotech focused on developing psychedelic therapies for mental health and addiction, with a diverse drug pipeline that includes psilocybin, LSD, and MDMA.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the publication of a study on the interaction between the SSRI escitalopram and psilocybin effects in healthy volunteers. Conducted by the University Hospital Basel, the study revealed that escitalopram did not significantly affect the positive mood effects of psilocybin but reduced negative outcomes like anxiety. The findings suggest that psilocybin can be administered without stopping escitalopram, paving the way for future research in clinical settings.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has initiated recruitment for a randomized placebo-controlled study to evaluate the effects of low-dose LSD on neuroplasticity and various cognitive measures. Conducted by Dr. Kim Kuypers from Maastricht University, the study aims to explore whether the timing of LSD administration influences its impact. The research focuses on measuring BDNF plasma levels, sleep, mood, cognitive performance, and immune response. This innovative study design combines digital and traditional methods to shed light on the potential benefits of microdosing psychedelics.
MindMed (NASDAQ: MNMD) reported its financial results for Q3 2021, showcasing a cash balance of $145.9 million as of September 30, 2021, up from $80.1 million at the end of 2020. However, the company faced a net loss of $24.3 million for the quarter, compared to $8.6 million in Q3 2020. Operating cash outflows rose significantly, amounting to $10.8 million in Q3 2021 versus $5.8 million in Q3 2020. The firm appointed new board members and expanded its scientific advisory board, enhancing its drug development efforts in psychedelic-inspired therapies.
On November 12, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that its CEO, Robert Barrow, will speak at the Jefferies 2021 London Healthcare Conference from November 16-19. The management team will be available for both in-person and virtual one-on-one meetings. A webcast of Barrow's presentation will be available on-demand starting November 17 at 9:20 AM GMT. MindMed is focused on developing psychedelic-inspired therapies for mental illness.